Trial Profile
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics; Proof of concept
- Sponsors Relypsa
- 28 Apr 2016 Results published in a Relypsa Inc. media release.
- 28 Apr 2016 According to Relypsa media release, data were presented at National Kidney Foundation 2016 Spring Clinical Meetings.
- 21 Apr 2016 According to Relypsa media release, data will be presented at National Kidney Foundation 2016 Spring Clinical Meetings.